Floatz logo

Navitoclax

Mantle Cell Lymphoma Refractory

Peter MacCallum Cancer Centre, AustraliaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

172 Active assets in the Mantle Cell Lymphoma Refractory cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Ruijin Hospital
Phase 4BBB
Bendamustine
Czech Lymphoma Study Group
Phase 2BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BBB
VINCRISTINE SULFATE
M.D. Anderson Cancer Center
Phase 2BBB
Busulphan
City of Hope Medical Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Navitoclax is also rated in:

neoplasmDormant
B
Indicative ·
58 / 100
View asset →
T-lymphoblastic lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
refractory malignant neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →